Lambda-CyhalothrinCAS No 91465-08-6CIPAC No 463 | A 1:1 mixture of:(R)-α-cyano-3-phenoxybenzyl (1S,3S)-3-[(Z)-2-chloro-3,3,3-trifluoropropenyl]-2,2-dimethylcyclopropanecarboxylate and (S)-α-cyano-3-phenoxybenzyl (1R,3R)-3-[(Z)-2-chloro-3,3,3-trifluoropropenyl]-2,2-dimethylcyclopropanecarboxylate or of (R)-α-cyano-3-phenoxybenzyl (1S)-cis-3-[(Z)-2-chloro-3,3,3-trifluoropropenyl]-2,2-dimethylcyclopropanecarboxylate and (S)-α-cyano-3-phenoxybenzyl (1R)-cis-3-[(Z)-2-chloro-3,3,3-trifluoropropenyl]-2,2-dimethylcyclopropanecarboxylate | 900 g/kg | 1 April 2016 | 31 March 2023 | For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on lambda-cyhalothrin, and in particular Appendices I and II thereof, shall be taken into account.In this overall assessment Member States shall pay particular attention to the:- (a)protection of operators, workers and bystanders;
- (b)metabolites potentially formed in processed commodities;
- (c)risk to aquatic organisms, mammals and non-target arthropods.
Conditions of use shall include risk mitigation measures, where appropriate.The applicants shall submit confirmatory information as regards:- 1.a systematic review to assess the evidence available as regards potential sperm effects linked to exposure to lambda-cyhalothrin using guidance available (e.g. EFSA GD on Systematic Review methodology, 2010);
- 2.toxicological information to assess the toxicological profile of the metabolites V (PBA) and XXIII (PBA(OH)).
The applicants shall submit those information to the Commission, the Member States and the Authority by 1 April 2018. |